Current NAFLD drug developmental effort centers on repurposing fibric acid derivatives, which are lipid-lowering PPARα agonists and insulin sensitivity–improving PPARγ agonists, thiazolidinediones, but the clinical trials yielded mixed results [3, 4]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.